Daewoong Pharmaceutical (069620) Stock Outlook 2026: Nabota's US Push and a Trio of Homegrown Drugs
A deep, qualitative 2026 outlook on Daewoong Pharmaceutical (KRX 069620): the Nabota botulinum toxin (sold as Jeuveau in the US), the winding down of the Medytox litigation, the P-CAB reflux drug Fexuclue, the SGLT-2 diabetes drug Envlo, overseas license-out royalties, the pipeline, and the R&D cost burden for global investors.
Daewoong Pharmaceutical 069620 Korea Stocks